GLP-1 agonists and other weight loss drugs may be beneficial in treating psoriatic arthritis and other rheumatic diseases. These medications have potential immunomodulatory effects and could help patients achieve treatment goals. Obesity is a risk factor for developing psoriatic arthritis and can reduce the effectiveness of treatment. Case reports suggest that weight loss drugs alone could benefit patients with psoriatic arthritis. Further research is needed to explore combination therapy with weight loss drugs and immunomodulatory medications. Overall, weight loss drugs may offer benefits across a spectrum of rheumatic diseases, but caution is needed when interpreting individual case reports.
Source link
Weight loss drugs may aid rheumatic disease treatment
